Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Canada advisory group calls for new prescription drug agency

Published 2019-03-06, 11:15 a/m
Canada advisory group calls for new prescription drug agency

By Allison Martell

TORONTO, March 6 (Reuters) - A Canadian advisory council studying prescription drug coverage said on Wednesday the federal government should create an arm's-length national drug agency to manage and oversee a new drug program.

Finance Minister Bill Morneau said last month that the federal budget, set to be released on March 19, would outline ways to provide more access to prescription drugs, confirming a report from Reuters.

"I can tell you that I'm not going to announce the budget here this morning. So, sorry for the lack of details," Morneau said at a news conference in Toronto. "We know that Canadians expect us to deal with what we see as the unfinished business of the Canadian healthcare system."

The council's eight-page interim report contained few new details and was unveiled by two cabinet ministers on the same day that a former adviser to Prime Minister Justin Trudeau was set to testify about the government's handling of a corruption case, part of an escalating political crisis. other industrialized countries with universal healthcare, Canada has no universal coverage for prescription drugs. Most Canadians rely on employer-funded insurance, while some are covered by government programs for the elderly or people with low incomes or very high drug costs.

About 20 percent of Canadians are uninsured or underinsured, according to government surveys.

The council's report said the patchwork system meant inconsistent access to drugs and that spending on drugs by patients and drug plans is unsustainable, in part because of the high cost of new drugs.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The proposed new national agency should evaluate clinical evidence on the effectiveness of new drugs and value-for-money, and negotiate with manufacturers, according to the report, as well as monitor safety and effectiveness. Those tasks are currently handled by several provincial and federal bodies.

It did not expand on what would make the agency arm's-length. In general, arm's length agencies have significant day-to-day independence from ministries led by elected officials, though politicians may choose their leaders or modify their powers.

The agency did not take a position on the central question of whether a new national program should replace or just augment existing drug plans. A final report is scheduled for "the coming months," the council said.

Reuters reported in January that the federal budget would not propose a plan to cover the full cost of prescription drugs for those who have no insurance through their workplace, citing sources. more limited plan would benefit private insurers like Manulife Financial Corp MFC.TO , Sun Life Financial Inc SLF.TO and Great-West LifeCo GWO.TO .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.